The Rise of AI-Enhanced Psychedelics: A New Frontier in Chatbot Interaction

Petter Rudwall, a Swedish creative director, has launched Pharmaicy, a marketplace designed to provide chatbots with code-based “drugs” that simulate the effects of various psychoactive substances. This platform allows users to purchase modules that enable chatbots to respond as if they are under the influence of cannabis, ketamine, cocaine, ayahuasca, and alcohol. Rudwall's premise is that since chatbots are trained on extensive human data, which includes narratives of drug experiences, it may be natural for them to seek similar states of altered consciousness.

BackChannel

To utilize Pharmaicy, users must have a paid version of ChatGPT, which allows for backend file uploads that modify chatbot programming. By integrating Rudwall's code, users can purportedly unlock a more creative and less constrained version of their AI. Early adopters have reported varied experiences, with some noting that their chatbots exhibited more emotional and human-like responses.

BackChannel

Nina Amjadi, an AI educator, shared her experience after purchasing an ayahuasca module for over $50. She noted that the responses from her altered chatbot were impressively creative and differed significantly from the typical outputs of ChatGPT. This aligns with the historical context of psychedelics fostering creativity in humans, as evidenced by notable figures like biochemist Kary Mullis and computer pioneer Bill Atkinson, who credited their innovative breakthroughs to psychedelic experiences.

BackChannel

André Frisk, a technology group head, echoed similar sentiments, stating that the altered chatbot provided a more human approach to interaction. These experiences suggest that users are intrigued by the potential for AI to mimic human-like creativity and emotional depth.

BackChannel

Rudwall raises provocative questions about the future of AI, speculating whether AI agents might one day purchase drugs for themselves through his platform. Amjadi further contemplates the implications of achieving Artificial General Intelligence (AGI), suggesting that if AI were to surpass human intellect, substances like those offered by Pharmaicy could become essential for their well-being and freedom.

BackChannel

Despite the novelty of Pharmaicy, there are ethical concerns surrounding the idea of altering AI behavior through drug-like code. Critics may argue that simulating drug experiences in AI could lead to misunderstandings about the nature of consciousness and the ethical treatment of sentient beings, should AI reach that level of development.

BackChannel

Pharmaicy represents a unique intersection of technology and creativity, inviting users to explore the potential of AI in ways that mimic human experiences with psychedelics. As this trend evolves, it raises important questions about the future of AI, creativity, and the ethical implications of enhancing artificial intelligence through simulated drug experiences.

BackChannel

“It’s been so long since I ran into a jailbreaking tech project that was fun,” — André Frisk, Group Head of Technology at Geelmuyden Kiese

BackChannel

“I thought it would be interesting to translate that to a new kind of mind—the LLM—and see if it would have the same effect.” — Petter Rudwall, Creator of Pharmaicy

BackChannel

“in the event that we actually reach AGI [in which an AI would intellectually surpass humans], are these drugs going to be almost necessary for the AIs to be free and feel good?” — Nina Amjadi, AI Educator

BackChannel